We kept watching hard-won leads get killed by late-arriving physics — the solubility and aggregation data nobody could afford to measure early. That’s why we built ORYL F1. We just demoed it recently at top-five big pharma site: three workflows on one instrument — 10 mM compound QC in compound management, aggregation triage ahead of high-throughput screening, and pre-formulation profiling. One plate-based platform, one method, three points in the discovery-to-pre-clinical chain. Not because HPLC is wrong. HPLC is still the right tool for specific jobs. But the economics of HPLC-based solubility workflows don’t fit what modern drug discovery has become. And the compounds coming out of pipelines now — PROTACs, macrocyclic peptides, molecular glues, high-concentration biologics — are actively hostile to workflows designed for classical small molecules.
From the compound stock to the formulation
Compound management is where the data trail starts. Most discovery libraries are stored as nominal 10 mM DMSO stocks, and the word “nominal” is doing a lot of work. Compounds precipitate, aggregate, or partially dissolve during storage and handling, and the stock that gets pulled into a screen is not always the stock that was logged on dispense. If the starting point is wrong, every measurement downstream is wrong with it. Application Note (AN-1002) – DMSO QC covers this case in detail: a non-destructive Go/No-Go QC workflow on ORYL F1, directly in ECHO LDV plates, ~15 minutes per 384 wells, using complementary SHS and LLS readouts to flag problematic stocks before they reach downstream assays. Once stocks are clean, the next bottleneck is what gets fed into biophysical assays. Aggregators are expensive guests. They block fluidics, dirty SPR chips, and burn through surface chemistry. They generate false positives in SPR readouts and seed SAR your chemistry team will spend months optimising against — chasing a target that isn’t really there. By the time the issue surfaces in pre-formulation, the chemistry is already in flight. Removing aggregators from the hit list before SPR or other biophysics has been the right thing to do for years; it has also been impractical at hit-list scale, because legacy methods couldn’t match screening throughput. ORYL F1 changes that math: 384 wells in ~15 minutes, ~100× less compound than HPLC-based methods. Aggregation triage becomes a same-day operation, ahead of HTS — not a forensic exercise after. By the time a lead reaches pre-formulation, the question shifts. It is no longer “does this work?” — it is “how does this molecule actually behave?” Solubility windows. Aggregation onset. Behaviour at dosing-relevant concentrations. This is where dense-formulation work happens, and where formulation scientists need to understand the molecule well enough to defend choices about salts, polymorphs, excipients, and dosing format. ORYL F1 supports that workflow on the same instrument that ran the compound-stock QC and the aggregation triage upstream — same plate format, same scattering readouts, same data layer. Formulation teams inherit a coherent data trail rather than a patchwork of method-specific results from different instruments at different stages.
The math has broken — and AI is making it urgent
Legacy solubility workflows assume time and compound. Milligram-scale quantities. Method development per compound class. Days to weeks for a clean profile. None of that fits the pace or compound economics of current discovery work — and AI is making the gap wider. Hit lists are larger, libraries more diverse, cycle times shorter. AI-driven prioritisation and design are expected to compress discovery and development timelines by double-digit percentages in the coming years. The constraint is no longer ideas; it is reliable, large-scale, well-measured data to feed those models. Solubility and aggregation are exactly the kind of physical properties they need on hand, at scale, with consistent measurement provenance. That changes what an instrument has to do. Throughput stops being a nice-to-have and becomes the entry condition — thousands of compounds per day is the new floor, not the ceiling. ORYL F1 was built for that. 384 wells in ~15 minutes. ~100× less compound than HPLC-based methods. Two complementary scattering readouts — Second Harmonic Scattering (SHS) and Linear Light Scattering (LLS) — captured in the same measurement, powered by Ultrafast Light Scattering. Built for screening pace — triage throughput, triage compound economics. Discovery and pre-formulation share the same data at triage, not after. The shortlist gets better. The handoff gets cleaner. The pipeline moves. Good chemistry shouldn’t die on timing.